In gene therapy manufacturing, viral vectors have long been the primary method for gene modification. However, recent innovations, combined with the evolving demands of the genetic medicines market, are driving a shift toward non-viral technologies. To address this need, the research team at Touchlight, leaders in the industrialisation of cell-free DNA and its application in genetic medicines, initiated development of a novel platform named Megabulb DNA (mbDNA™).

In this executive summary, you’ll learn:

• Why mbDNA™ is redefining precision gene editing
• How mbDNA dramatically improves cell viability and edited cell yields
• How mbDNA delivers proven performance in real-world applications with ElevateBio